- Open Clinical Trials
- Closed Clinical Trials
- 2022-2026 Research Strategy
- Research Achievements
- Research Development and Funding
- BCT Trials & Projects Summary
- Clinical Fellowship Program
- International Fellowship Support
- Translational Research
- What is a Clinical Trial?
- Why Participate in a Clinical Trial?
- Research Blog
- Participating Institutions
- International Collaboration
- Annual Scientific Meeting
- Travel Grants and Awards
- Our Impact
- Researcher Login
A one-off grant of up to $50,000 per year, over 1-2 years. Discretionary Funding grants are primarily to support small scale research studies such as Pilot studies that have the potential to lead to BCT-coordinated trials. Funding may be also be considered for sub-studies of protocols BCT is currently involved in, small-scale translational research studies, or projects related to research methodology.
Clinical Trial Development Funding:
Supports longer-term research projects (minimum three years) of high strategic value that are unfunded. Projects must be coordinated by the BCT Trials Department.
An investigator-initiated Discretionary Funding project or Clinical Trial proposal must be submitted using the Concept Proposal Form to the BCT Operational Executive. The BCT Operational Executive initially reviews the Concept Proposal to ensure that it meets the aims of the BCT research program and does not compete with a project that may be in the trials pipeline.
Applications are encouraged from non-BCT members. However, for all projects that are approved for ongoing development, investigators must become BCT members. Click here for further information about BCT membership.
Additional information about the BCT trial development process is available to members via the Research section of the website. Refer Clinical Trials/ Investigator Resources tab or via link: Research Development and Funding.
Concept Development Working Group
An approved Concept Proposal is developed with a Concept Development Working Group (CDWG), coordinated by a Craft Group Lead. Researchers may already have specialist researchers to form a CDWG, however the Operational Executive will provide guidance if required. The CDWG must consist of at least two specialist area experts, a statistician and a Consumer Advisory Panel representative. The CDWG develops the Concept Proposal into a Project Synopsis for a Discretionary Funding Application or potential Clinical Trial.
Peer Review and SAC Review
Peer Review of the Project Synopsis is coordinated by the Operational Executive. At least two independent experts, a statistician and the CAP will review synopses. The peer reviews and the Project Synopsis will be presented for discussion and assessment by the Scientific Advisory Committee (SAC). The SAC evaluates the scientific merit and feasibility of project proposals and either:
- Determines the next steps required to develop the proposal into a Clinical Trial Protocol*; or
- Approves the Discretionary Funding Application.
* Funding options are also considered during this process. If BCT support for a grant application is needed, then BCT support must be confirmed (usually after peer- and SAC-review of the Project Synopsis) and sufficient protocol logistics developed to allow budget formulation. Supply of study treatment or other in-kind support must be confirmed.
BCT Investigator-Initiated Trials
The following clinical trials have been developed via the BCT Clinical Trials Development process:
Discretionary Funding Projects
The following projects have been funded by BCT Discretionary Funding:
- TROG 14.04: Multicentre Study of Feasibility and Impact on Anxiety of DIBH in Breast Cancer Patients
- Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials
- Genitourinary symptoms in women with breast cancer: what do oncology health professionals think and do about them?
- The Implementation of a Decision Aid for women with early-stage breast cancer considering prophylactic mastectomy: a pilot study
- Treatment of vaginal atrophy using fractional microablative CO2 laser in post-menopausal women with breast cancer on aromatase inhibitors: A pilot study
- MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer and BCT Research Blog
- The timeline and quality of life implications of madarosis in patients undergoing cytotoxic chemotherapy for breast malignancy
- Development of a patient decision aid for women with early stage unilateral breast cancer considering contralateral prophylactic mastectomy
- The SEGMENT study: A next generation SEquencing panel for GenoMic alterations for advanced brEast caNcer patienTs and BCT Research Blog
- iPrevent a web-based decision support tool for breast cancer risk assessment and management
- ANZ1302 Aromatase Inhibitor induced musculoskeletal syndrome (AIMSS) and BCT Research Blog